ReviewCNS neuroscience & therapeutics2011
Parkinson's disease dementia and potential therapeutic strategies.
Review in CNS neuroscience & therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Epilepsy and EEG abnormalities in neurodegenerative dementias: toward a system epilepsy framework.Frontiers in aging neuroscience · 2026Review
- Neolitsea sericea attenuates oxidative stress-induced cell death in human neuroblastoma SH-SY5Y cells via MAPK and NF-κB pathway Inhibition.Molecular biology reports · 2025Article
- Durian fruit pulp extract enhances intracellular glutathione levels, mitigating oxidative stress and inflammation for neuroprotection.Scientific reports · 2024Article
- Alternative Therapies for Non-Motor Symptoms in Parkinson's Disease: A Mini Review.Neuropsychiatric disease and treatment · 2024Review
- The Neuroprotective Effects ofInternational journal of molecular sciences · 2023Article
- The alpha-synuclein oligomers activate nuclear factor of activated T-cell (NFAT) modulating synaptic homeostasis and apoptosis.Molecular medicine (Cambridge, Mass.) · 2023Article
- Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.Dementia & neuropsychologia · 2022Article
- Resting-state electroencephalographic correlates of cognitive reserve: Moderating the age-related worsening in cognitive function.Frontiers in aging neuroscience · 2022Article
- Ethanol Extract ofInternational journal of molecular sciences · 2021Article
- Melandrii Herba Extract Attenuates H₂O₂-Induced Neurotoxicity in Human Neuroblastoma SH-SY5Y Cells and Scopolamine-Induced Memory Impairment in Mice.Molecules (Basel, Switzerland) · 2017Article
- Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2016Article
- Converging mediators from immune and trophic pathways to identify Parkinson disease dementia.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Endoplasmic reticulum stress: relevance and therapeutics in central nervous system diseases.Molecular neurobiology · 2015Review
- Article
- Oxidative stress is not involved in motion sickness in mice.CNS neuroscience & therapeutics · 2013Article
- Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis.European radiology · 2013Article
- Edaravone protects HT22 neurons from H2O2-induced apoptosis by inhibiting the MAPK signaling pathway.CNS neuroscience & therapeutics · 2013Article
- Cumulative exposure to lead and cognition in persons with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2013Article
- RhTFAM treatment stimulates mitochondrial oxidative metabolism and improves memory in aged mice.Aging · 2012Article
- α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.Journal of neurochemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia in Parkinson's disease (PD-D) has only been acknowledged in the recent three decades, but research in this field has accelerated. The purpose of this review was to discuss advances in PD-D regarding biomarker correlates and potential therapeutic targets. Attention and executive dysfunction, memory deficits that improve with cueing, and visual hallucinations are characteristic in PD-D. PD-D dramatically increases the disability and misery of the disease. Current treatment for PD-D is symptomatic, modest, and only transiently effective. There is wide agreement that more effective treatment is needed, but this will require more knowledge about PD-D pathophysiology. Advances in the pathogenesis of PD have focused on the substantia nigra, which is the location from where the pathophysiology of motor symptoms primarily arises in initial stages. In contradistinction, pathology studies have suggested that cognitive decline correlates with cortical and subcortical-cortical projection pathway abnormalities. There is evidence that substantia nigra mechanisms, including protein aggregation of α-synuclein (e.g., Lewy bodies) may also play a role in cortical neuron degeneration. Other different mechanisms, such as Alzheimer's disease pathology (e.g., Aβ aggregation) may be operant for PD-D. Biomarkers of various types are being proposed for the study of PD-D as well as for objective measures of PD-D prediction and progression. Therapeutic targets are currently derived mostly from general PD neurodegeneration research rather than cortical PD neurodegeneration per se. Protein aggregation, genes that are associated with PD, oxidative stress, inflammation, and trophic factors constitute the major classes of therapeutic targets for PD-D. More research is needed on the specific aspects of cortical dysfunction and degeneration that create PD-D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.